Mild side effects may include redness, swelling or light bruising at the injection site
Several treatment options have emerged that promote clearer skin, such as topical creams, chemical peels, and laser therapies
Ongoing phase 3 trials are in progress, and CagriSema is currently under FDA review, with a decision expected in late 2026
In Texas, peptide prescriptions must come from a licensed prescriber: a medical doctor (MD or DO), nurse practitioner (NP), or physician assistant (PA)
The neurotrophic agents capable of facilitating synaptogenesis and neurogenesis include nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3, and neurotrophin-4 [34,35]
Mechanism of Action: The "Push-Pull" Effect